Catalog No.
EVV03201
Expression system
Mammalian Cells
Species
Human immunodeficiency virus type 2 subtype A (isolate NIH-Z) (HIV-2)
Protein length
Lys23-Thr501
Predicted molecular weight
58.11 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P05883
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates., PMID:37240423
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs., PMID:35563157
Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2., PMID:33669351
The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains., PMID:31507190
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors., PMID:31277353
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428
Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages., PMID:30496280
Potent suppression of HIV-1 cell attachment by Kudzu root extract., PMID:30236131
Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses., PMID:29936340
Characterization of twin-cysteine motif in the V2-loop region of gp120 in primate lentiviruses., PMID:29729526
eCD4-Ig Variants That More Potently Neutralize HIV-1., PMID:29593050
Characterization of Envelope Surface Glycoprotein from HIV-2 Primary Isolates with Different Coreceptor Usage Profile., PMID:29258330
A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support., PMID:27998283
Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus., PMID:27535053
The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection., PMID:27117672
The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition., PMID:26816344
Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques., PMID:26676777
Structure of an HIV-2 gp120 in Complex with CD4., PMID:26608312
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein., PMID:26387945
NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles., PMID:25700718
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency., PMID:25673728
Stoichiometric parameters of HIV-1 entry., PMID:25463598
Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family., PMID:24970741
Synthesis, biophysical characterization and anti-HIV activity of d(TG3AG) Quadruplexes bearing hydrophobic tails at the 5'-end., PMID:24433967
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models., PMID:24145548
A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization., PMID:23936006
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism., PMID:23151495
Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA., PMID:23098841
HIV progression to AIDS: bioinformatics approach to determining the mechanism of action., PMID:22998236
Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors., PMID:21902586
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1., PMID:21459115
Discovery of novel anti-HIV active G-quadruplex-forming oligonucleotides., PMID:21305065
Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages., PMID:20610711
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent., PMID:20439611
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity., PMID:20357769
3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1., PMID:20194691
Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use., PMID:20047920
Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates., PMID:19774680
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)., PMID:19161986
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma., PMID:19019969
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C., PMID:18815292
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists., PMID:17609282
Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles., PMID:17510784
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors., PMID:17409160
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion., PMID:17144914
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation., PMID:16648135
Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic., PMID:16622871
Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125., PMID:16611061
Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens., PMID:16432590
For research use only. Not for human or drug use.
